[{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"PF-08046052","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lava Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Lava Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Batavia Bioscience","sponsor":"Candel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2024","type":"Partnership","leadProduct":"CAN-3110","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Batavia Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Batavia Bioscience \/ Candel Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Batavia Bioscience \/ Candel Therapeutics"},{"orgOrder":0,"company":"Merus","sponsor":"Chiltern International Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Petosemtamab","moa":"EGFR\/LGR5","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merus \/ Chiltern International Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Chiltern International Ltd"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"LAVA-051","moa":"CD1d","graph1":"Oncology","graph2":"Phase I","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lava Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Lava Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Halix BV","sponsor":"NovalGen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"NVG-111","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Halix BV","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Halix BV \/ NovalGen","highestDevelopmentStatusID":"6","companyTruncated":"Halix BV \/ NovalGen"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"LAVA-1266","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lava Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SkylineDx","sponsor":"BioInvent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"BI-1206","moa":"||CD32B","graph1":"Oncology","graph2":"Phase I","graph3":"SkylineDx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SkylineDx \/ BioInvent","highestDevelopmentStatusID":"6","companyTruncated":"SkylineDx \/ BioInvent"},{"orgOrder":0,"company":"Sairopa","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"ADU-1604","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Sairopa","amount2":0.34000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.34000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Sairopa \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Sairopa \/ Exelixis"},{"orgOrder":0,"company":"Gadeta","sponsor":"Clade Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"GDT002","moa":"Gamma-delta-T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Gadeta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gadeta \/ Clade Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Gadeta \/ Clade Therapeutics"},{"orgOrder":0,"company":"Gadeta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GDT002","moa":"Gamma-delta-T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Gadeta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gadeta \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gadeta \/ Inapplicable"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"oNKord","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Glycostem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycostem Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Glycostem Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Niraparib","moa":"||HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Byondis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Byondis \/ Inapplicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"BYON3521","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Byondis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Byondis \/ Inapplicable"},{"orgOrder":0,"company":"InteRNA Technologies","sponsor":"Dutch Government","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Funding","leadProduct":"INT-1B3","moa":"Adenosine A2A receptor","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InteRNA Technologies \/ Dutch Government","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA Technologies \/ Dutch Government"},{"orgOrder":0,"company":"InteRNA Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"INT-1B3","moa":"Adenosine A2A receptor","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InteRNA Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA Technologies \/ Inapplicable"},{"orgOrder":0,"company":"InteRNA Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"INT-1B3","moa":"Adenosine A2A receptor","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InteRNA Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA Technologies \/ Inapplicable"},{"orgOrder":0,"company":"InteRNA Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"INT-1B3","moa":"Adenosine A2A receptor","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InteRNA Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Petosemtamab","moa":"EGFR\/LGR5","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"MCLA-145","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"MCLA-145","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MCLA-145","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Incyte Corporation"},{"orgOrder":0,"company":"Kling Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"KBA1412","moa":"||CD9","graph1":"Oncology","graph2":"Phase I","graph3":"Kling Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kling Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kling Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Synaffix","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2023","type":"Licensing Agreement","leadProduct":"IBI343","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Synaffix \/ Innovent Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Synaffix \/ Innovent Biologics"},{"orgOrder":0,"company":"Byondis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"SYD1875","moa":"5T4 protein","graph1":"Oncology","graph2":"Phase I","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Byondis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Byondis \/ Inapplicable"},{"orgOrder":0,"company":"Pepscan","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Pepscan","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pepscan \/ Mayo Clinic","highestDevelopmentStatusID":"6","companyTruncated":"Pepscan \/ Mayo Clinic"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : LAVA-1266 is a potent bi-specific, T cell engager that targets CD123+ tumor cells. It is being evaluated for the hematologic cancers including acute myeloid leukemia & myelodysplastic syndrome.

                          Product Name : LAVA-1266

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          January 10, 2025

                          Lead Product(s) : LAVA-1266

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The collaboration combines Exelixis' proven oncology drug development and commercialization track record with Sairopa's expertise. ADU-1805 is currently being evaluated for melanoma.

                          Product Name : ADU-1604

                          Product Type : Other Large Molecule

                          Upfront Cash : $40.0 million

                          December 17, 2024

                          Lead Product(s) : ADU-1604

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Exelixis

                          Deal Size : $335.0 million

                          Deal Type : Collaboration

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Lava will receive milestone payments for SGN-EGFRd2 (PF-08046052), evaluated for colorectal neoplasms and non-small-cell lung carcinoma treatment.

                          Product Name : SGN-EGFRd2

                          Product Type : Other Large Molecule

                          Upfront Cash : $50.0 million

                          May 03, 2024

                          Lead Product(s) : PF-08046052

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Pfizer Inc

                          Deal Size : $700.0 million

                          Deal Type : Agreement

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The partnership aims to accelerate the development and production of CAN-3110, an oncolytic viral immunotherapy for glioma brain tumors, based on a replication attenuated Herpes Simplex Virus (HSV).

                          Product Name : CAN-3110

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          March 21, 2024

                          Lead Product(s) : CAN-3110,Cyclophosphamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Candel Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates, including IBI343, a recombinant human anti-Claudin 18.2 monoclonal antibody-drug conjugate.

                          Product Name : IBI343

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          June 12, 2023

                          Lead Product(s) : IBI343

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Innovent Biologics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The acquisition will provide Clade with preclinical cell therapy programs, g/d TCR discovery engine and a suite of cell enhancement to improve anti-tumor activity of cell therapies.

                          Product Name : GDT002

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          February 10, 2023

                          Lead Product(s) : GDT002

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Clade Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          07

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : KBA1412 is a first in class fully human anti-CD9 antibody based on an antibody produced by circulating B cells in the blood of a cancer survivor.

                          Product Name : KBA1412

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          September 29, 2022

                          Lead Product(s) : KBA1412,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : BYON3521.001 intends to evaluate safety, PK and preliminary efficacy of BYON3521 in up to 150 patients aged 18 or over with histologically confirmed c-MET-expressing, MET-amplified or MET-mutated (except exon 14 mutated) locally advanced or metastatic so...

                          Product Name : BYON3521

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          August 25, 2022

                          Lead Product(s) : BYON3521

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : PneoVCA is designed to target certain proteins (neoantigens) on individuals’ tumor cells. Combination immunotherapy with mAB, such as pembrolizumab, may help the body’s immune system attack the cancer and thereby interfere with ability of tumor cells...

                          Product Name : PneoVCA

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          June 28, 2022

                          Lead Product(s) : PneoVCA,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Mayo Clinic

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : MCLA-158, (petosemtamab) exhibits unique therapeutic properties such as potent growth inhibition of KRAS mutant CRC organoids, blockade of metastasis initiation, and inhibition of tumor outgrowth in preclinical models of different tumor types.

                          Product Name : MCLA-158

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 25, 2022

                          Lead Product(s) : Petosemtamab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank